Adoptive T-cell therapy – Solutions for T-cell engineering and expansion

Adoptive T-cell therapy is a promising development in cancer immunotherapy and the number of clinical trials is rapidly increasing every year. However, method optimization is still necessary to produce T cells at large scale. In this webinar, we will discuss tools for improving the T-cell engineering and expansion process to maximize the therapeutic potential of patient-derived T cells.

The webinar will cover the following topics:

  • Efficient serum-free T-cell culture using LymphoONE™ Medium
  • Benefits of RetroNectin® stimulation to ensure a high proportion of naïve-like T cells
  • Footprint-free T-cell engineering
  • T-cell engineering using viral delivery

Cornelia Hampe, PhD


Cornelia Hampe, PhD
Senior Product Manager
Takara Bio Europe